An interventional study of APL-1702 and APL-1702 in Cervical Intraepithelial Neoplasia Grade 2/3 and Human Papillomavirus Infection, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Xiangya Hospital of Central South University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Papillomavirus Infections with a site in China — 26 open to participants now, 39 under way, 10 of them phase 3. Papillomavirus Infections · China.
Among the 68 studies in Papillomavirus Infections with a site in China, this one is the 31st largest by planned enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2025, is one of 6 with no phase, reaches primary completion later than 26 of the 38 other live ones, and was the 68th registered.
581 studies on the registry are indexed under Papillomavirus Infections; 134 are open to participants now.
Browse Papillomavirus Infections studies →26 of the 68 studies in Papillomavirus Infections with a site in China are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in China
Ages 10–45 · Women only · Healthy volunteers
Beijing Xunsheng Biomedical Research Co., Ltd. · Sites in China
Ages 18–64 · Women only
Shanghai Mianyi Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Women only
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 25–65 · Women only · Healthy volunteers
The First Hospital of Jilin University · Sites in China
Ages 26–65 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Papillomavirus Infections studies recruiting now, 39 (44%) set no upper age limit and 44 (50%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 9 · Phase 3 18 · Phase 4 3
First in 2005; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 159 is below the median of 227 across 405 interventional studies indexed under Papillomavirus Infections.
Median enrollment 510 across the 44 interventional studies, 2,600 across the 24 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 68 have an industry lead sponsor. The 10 most frequent:
Xiangya Hospital of Central South University is the lead sponsor of 176 studies on the registry; 79 are open to participants now.
Xiangya Hospital of Central South University has 1 study filed under Papillomavirus Infections — fewer than ten, so there is no comparison to draw.
5 of the studies in Papillomavirus Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07833852Shanghai Zerun Biotechnology Co.,LtdLong-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005 | 2026-12 |
| NCT06137352Fujian Maternity and Child Health HospitalTwo Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity | 2026-12-31 |
| NCT07820241Shanghai Zerun Biotechnology Co.,LtdLong-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004 | 2027-04 |
| NCT05371353Shanghai Bovax Biotechnology Co., Ltd.Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | 2027-05 |
| NCT07942779Beijing Xunsheng Biomedical Research Co., Ltd.AVL-102 for the Treatment of HPV 16/18/52/58-Related High-Grade Lesions | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 68 studies in Papillomavirus Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This investigator-initiated, open-label, exploratory study evaluates the safety and preliminary efficacy of APL-1702 photodynamic therapy in participants with high-risk human papillomavirus (hrHPV)-positive cervical intraepithelial neoplasia grade 2 (CIN2) or grade 3 (CIN3). Part 1 enrolls adults with CIN2 into six treatment-regimen groups to identify a preferred regimen, primarily on the basis of histological regression at Week 24 after the first treatment. Part 2 enrolls adults aged 18 to 45 years with hrHPV-positive CIN3 and evaluates three treatments administered at Day 0, Month 1, and Month 3. Participants are assessed for histological regression, hrHPV clearance, and safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 3 treatments.
Drug: APL-1702
Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 6 treatments.
Drug: APL-1702
Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 3 treatments.
Drug: APL-1702
Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 6 treatments.
Drug: APL-1702
Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 3 treatments.
Drug: APL-1702
Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 6 treatments.
Drug: APL-1702
Adults aged 18 to 45 years with hrHPV-positive CIN3 receive a total of three APL-1702 treatments.
Drug: APL-1702
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3.
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6.
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3.
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3.
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6.
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).
Part 1: Histological regression rate at Week 24 after the first treatment
Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens.
Time frame: Week 24 after the first treatment
Part 2: Histological regression rate at Week 24 after the first treatment
Proportion of Part 2 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens.
Time frame: Week 24 after the first treatment
Part 1 hrHPV clearance rate
Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.
Time frame: 28 days after the final treatment course and Week 24 after the first treatment
Part 1 incidence and characteristics of adverse events and serious adverse events
Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events.
Time frame: From informed consent through Week 96 after the first treatment
Part 1 long-term hrHPV clearance rate
Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.
Time frame: Weeks 36, 60, and 96 after the first treatment
Part 1 long-term histological regression rate
Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only.
Time frame: Weeks 36, 60, and 96 after the first treatment
Part 2 hrHPV clearance rate
Proportion of Part 2 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.
Time frame: Week 24 after the first treatment
Part 2 incidence and characteristics of adverse events and serious adverse events
Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events.
Time frame: From informed consent through Week 48 after the first treatment
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jan 2028, 32 months after the start.
Of 109 non-industry interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 32 months is above that.
Counting every sponsor, half of 118 studies reached it within 26 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiangya Hospital of Central South University →